“The consolidated partnership that has seen us alongside Sicob for years has the common objective of offering the best possible care for obese patients. Obesity is a complex disease that must be recognized and treated as such. This is why it is important to offer the best care and that patients rely on centers of excellence where, through a multidisciplinary approach, the patient is treated throughout his entire journey”. Patrick FataleGeneral Manager Ethicon Italia on the occasion of the 32nd National Congress of the Italian Obesity Surgery Society entitled ‘Obesity: in search of a new therapeutic alliance’, underway at Giardini Naxos (Messina).
Johnson & Johnson MedTech is present again this year at the Sicob event to reiterate its commitment to two fundamental aspects such as innovation and surgeon training. “We have invested a lot in training – observes Fatale – because we believe that in the hands of surgeons it is possible to work magic and treat patients in the best way. We have a project that aims to train young surgeons in the management of obese patients and increase not only surgical skills, but also increase the system’s ability to treat obese patients.”
Another fundamental aspect is that of communication, regarding which Fatale believes that, as there is “a stigma towards obesity, it is essential to work together with the scientific community to offer the best possible information to patients, so that they can choose the best treatment”.
A presence, that of Johnson & Johnson MedTech – reports uns note – which confirms the success of previous editions, with the organization of the usual Training Village, which includes two days of practical sessions dedicated to the training of the surgeons present at the event. And, again in relation to innovation, the general manager of Ethicon Italia reiterated that “this year for J&J MedTech the congress also represents an important opportunity to talk about the latest innovations at the service of bariatric surgery”. “For us, innovation is the heart of how we operate as a company – he explained – Every product we develop is the result of a careful study of the patient’s biology and anatomy and also of the surgeon’s use of the instrument itself. So we try to combine biology with technology and try to collect feedback from hundreds of surgeons when we develop a new product.” This year “we also bring our latest innovations here and confirm our commitment to reducing surgical complications and to greater sustainability and accessibility of care for patients” he concludes.
#Salute #Fatale #MedTech #Sicob #offer #care #obese #patients
